Table 4.
Comparison of the change in outcome measures during the double-blind period among the placebo and propranolol groups.
| Outcome Measure | Placebo | Propranolol | p |
|---|---|---|---|
| Primary outcome | |||
| Change in ESS | −0.35 ± 0.68 | −2.03 ± 1.7 | 0.009 |
| Secondary outcomes | |||
| Change in Hb level (g/dL) | 0.68 ± 0.01 | 1.96 ± 0.85 | 0.216 |
| Change in number of PC required | −0.20 ± 0.63 | −0.40 ± 0.69 | 0.029 |
| Change in number of IV iron doses required * | −0.20 ± 0.63 | −0.50 ± 0.97 | 0.304 |
| QOL | 6.11 ± 5.85 | 6.06 ± 5.90 | 0.986 |
ESS, epistaxis severity score; Hb, hemoglobin; PC, packed cells; IV, intravenous; QOL, quality of life. * Dose, Ferinject 500 mg.